Fludarabine in Treating Patients With Steroid-Resistant Chronic Graft- Versus-Host Disease
NCT00004194 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL
Last updated 2013-12-18
Summary
RATIONALE: Fludarabine may be an effective treatment for graft-versus-host disease caused by bone marrow transplantation.
PURPOSE: Phase I/II trial to study the effectiveness of fludarabine in treating patients who have chronic graft-versus-host disease that has not responded to steroid therapy.
Conditions
Interventions
- DRUG
-
fludarabine phosphate
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Jonsson Comprehensive Cancer Center
lead OTHER
Principal Investigators
-
Christos E. Emmanouilides, MD · Jonsson Comprehensive Cancer Center
Study Design
- Purpose
- SUPPORTIVE_CARE
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia
NCT00110058 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders
NCT00587054 ·Status: COMPLETED ·Phase: PHASE2
-
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
NCT00134004 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor
NCT00582933 ·Status: COMPLETED ·Phase: PHASE2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
NCT03314974 ·Status: RECRUITING ·Phase: PHASE2
-
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
NCT00448201 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support
NCT00506857 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
NCT00060424 ·Status: COMPLETED ·Phase: PHASE2
-
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
NCT00004904 ·Status: COMPLETED ·Phase: PHASE1
-
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
NCT00005799 ·Status: COMPLETED ·Phase: NA
-
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
NCT01056614 ·Status: COMPLETED ·Phase: PHASE2
-
Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma
NCT00006252 ·Status: COMPLETED ·Phase: PHASE2
-
Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer
NCT00346359 ·Status: COMPLETED ·Phase: PHASE2
-
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
NCT00397813 ·Status: COMPLETED ·Phase: PHASE2
-
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
NCT03333486 ·Status: TERMINATED ·Phase: PHASE2
-
S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma
NCT00121186 ·Status: TERMINATED ·Phase: PHASE2
-
Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia
NCT00005898 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
NCT00544115 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
NCT00301834 ·Status: COMPLETED ·Phase: PHASE2
-
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
NCT00085449 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease
NCT00385788 ·Status: COMPLETED ·Phase: PHASE2
-
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD
NCT00914940 ·Status: TERMINATED ·Phase: PHASE2
-
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
NCT06001385 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
NCT00006042 ·Status: COMPLETED ·Phase: PHASE1
-
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies
NCT00014235 ·Status: COMPLETED ·Phase: NA